InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240)

Description of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240)

Introduction

InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240) is a novel immunotherapy agent that has shown promising results in the treatment of various cancers. This bispecific antibody is designed to target both PD-1 and PD-L1, two important immune checkpoint proteins that play a critical role in regulating the immune response. In this article, we will discuss the structure, activity, and potential applications of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody.

Structure of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody

InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody is a recombinant humanized antibody that is composed of two different antigen-binding domains. One domain is specific for PD-1, while the other is specific for PD-L1. This dual targeting mechanism allows the antibody to simultaneously block the interaction between PD-1 and PD-L1, thereby preventing the suppression of T cell activity.

The antibody is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to their respective targets, while the constant regions provide stability and effector functions. The antibody has a molecular weight of approximately 150 kDa and is stable at physiological pH and temperature.

Activity of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody

The main activity of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody is to block the interaction between PD-1 and PD-L1. PD-1 is a receptor found on the surface of T cells, while PD-L1 is a ligand expressed on the surface of tumor cells and other immune cells. When PD-1 binds to PD-L1, it sends a signal to T cells to become inactive, allowing cancer cells to evade the immune system.

By targeting both PD-1 and PD-L1, InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody effectively blocks this signaling pathway and restores the activity of T cells. This results in enhanced anti-tumor immune responses and improved tumor control.

Therapeutic Target

The therapeutic target of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody is PD-1 and PD-L1, two important immune checkpoint proteins. These proteins are overexpressed in many types of cancer, including melanoma, lung cancer, and bladder cancer. By targeting these proteins, the antibody has the potential to treat a wide range of cancers.

Research Use

In addition to its potential as a therapeutic agent, InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody is also widely used in research studies. It has been used in preclinical studies to investigate the role of PD-1 and PD-L1 in cancer development and to evaluate the efficacy of various immunotherapies. The antibody has also been used in in vitro and in vivo experiments to study the mechanism of action of PD-1 and PD-L1 blockade.

Applications of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody

InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. It has the potential to be used as a monotherapy or in combination with other cancer therapies, such as chemotherapy and targeted therapy.

Additionally, the antibody has shown potential in treating cancers that are resistant to other immunotherapies, such as anti-PD-1 or anti-PD-L1 antibodies.